Literature DB >> 23521369

Undue industry influences that distort healthcare research, strategy, expenditure and practice: a review.

Emmanuel Stamatakis1, Richard Weiler, John P A Ioannidis.   

Abstract

BACKGROUND: Expenditure on industry products (mostly drugs and devices) has spiraled over the last 15 years and accounts for substantial part of healthcare expenditure. The enormous financial interests involved in the development and marketing of drugs and devices may have given excessive power to these industries to influence medical research, policy, and practice.
MATERIAL AND METHODS: Review of the literature and analysis of the multiple pathways through which the industry has directly or indirectly infiltrated the broader healthcare systems. We present the analysis of the industry influences at the following levels: (i) evidence base production, (ii) evidence synthesis, (iii) understanding of safety and harms issues, (iv) cost-effectiveness evaluation, (v) clinical practice guidelines formation, (vi) healthcare professional education, (vii) healthcare practice, (viii) healthcare consumer's decisions.
RESULTS: We located abundance of consistent evidence demonstrating that the industry has created means to intervene in all steps of the processes that determine healthcare research, strategy, expenditure, practice and education. As a result of these interferences, the benefits of drugs and other products are often exaggerated and their potential harms are downplayed, and clinical guidelines, medical practice, and healthcare expenditure decisions are biased.
CONCLUSION: To serve its interests, the industry masterfully influences evidence base production, evidence synthesis, understanding of harms issues, cost-effectiveness evaluations, clinical practice guidelines and healthcare professional education and also exerts direct influences on professional decisions and health consumers. There is an urgent need for regulation and other action towards redefining the mission of medicine towards a more objective and patient-, population- and society-benefit direction that is free from conflict of interests.
© 2013 Stichting European Society for Clinical Investigation Journal Foundation. Published by Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23521369     DOI: 10.1111/eci.12074

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  31 in total

1.  Cochrane in CORR ®: Industry Sponsorship and Research Outcome.

Authors:  Tahira Devji; Jason W Busse
Journal:  Clin Orthop Relat Res       Date:  2017-06-20       Impact factor: 4.176

Review 2.  Caring for patients with kidney disease: shifting the paradigm from evidence-based medicine to patient-centered care.

Authors:  Ann M O'Hare; Rudolph A Rodriguez; Christopher Barrett Bowling
Journal:  Nephrol Dial Transplant       Date:  2015-01-29       Impact factor: 5.992

3.  On the suppression of vaccination dissent.

Authors:  Brian Martin
Journal:  Sci Eng Ethics       Date:  2015-02       Impact factor: 3.525

4.  Trends in Drug Prescription Rates for Dementia: An Observational Population-Based Study in France, 2006-2014.

Authors:  Mathilde François; Jonathan Sicsic; Alexis Elbaz; Nathalie Pelletier Fleury
Journal:  Drugs Aging       Date:  2017-09       Impact factor: 3.923

Review 5.  Estrogen and selective estrogen receptor modulators (SERMs) for the treatment of acromegaly: a meta-analysis of published observational studies.

Authors:  Jennifer C Stone; Justin Clark; Ross Cuneo; Anthony W Russell; Suhail A R Doi
Journal:  Pituitary       Date:  2014-06       Impact factor: 4.107

6.  Potential Conflict of Interest and Bias in the RACGP's Smoking Cessation Guidelines: Are GPs Provided with the Best Advice on Smoking Cessation for their Patients?

Authors:  Ross MacKenzie; Wendy Rogers
Journal:  Public Health Ethics       Date:  2015-04-20       Impact factor: 1.940

Review 7.  Industry sponsorship and research outcome.

Authors:  Andreas Lundh; Joel Lexchin; Barbara Mintzes; Jeppe B Schroll; Lisa Bero
Journal:  Cochrane Database Syst Rev       Date:  2017-02-16

8.  Differential Globalization of Industry- and Non-Industry-Sponsored Clinical Trials.

Authors:  Ignacio Atal; Ludovic Trinquart; Raphaël Porcher; Philippe Ravaud
Journal:  PLoS One       Date:  2015-12-14       Impact factor: 3.240

9.  Blood pressure changes after renal denervation at 10 European expert centers.

Authors:  A Persu; Y Jin; M Azizi; M Baelen; S Völz; A Elvan; F Severino; J Rosa; A Adiyaman; F E Fadl Elmula; A Taylor; A Pechère-Bertschi; G Wuerzner; F Jokhaji; T Kahan; J Renkin; M Monge; P Widimský; L Jacobs; M Burnier; P B Mark; S E Kjeldsen; B Andersson; M Sapoval; J A Staessen
Journal:  J Hum Hypertens       Date:  2013-09-26       Impact factor: 3.012

Review 10.  Publication and other reporting biases in cognitive sciences: detection, prevalence, and prevention.

Authors:  John P A Ioannidis; Marcus R Munafò; Paolo Fusar-Poli; Brian A Nosek; Sean P David
Journal:  Trends Cogn Sci       Date:  2014-03-18       Impact factor: 20.229

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.